Peer review report 1 on “Ileal versus sigmoid neobladders as bladder substitute after radical cystectomy for bladder cancer: A meta-analysis”

2016 ◽  
Vol 25 ◽  
pp. 95
2018 ◽  
Vol 36 (6) ◽  
pp. 293-305 ◽  
Author(s):  
Andrea Mari ◽  
Shoji Kimura ◽  
Beat Foerster ◽  
Mohammad Abufaraj ◽  
David D'Andrea ◽  
...  

BMC Urology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Agus Rizal A. H. Hamid ◽  
Fanny Riana Ridwan ◽  
Dyandra Parikesit ◽  
Fina Widia ◽  
Chaidir Arif Mochtar ◽  
...  

Abstract Background Most patients with muscle-invasive bladder cancer (MIBC) developed metastasis within 2 years, even after radical cystectomy (RC). The recurrence rate of MIBC was more than 50% of the cases. A meta-analysis conducted by Yin et al. showed that neoadjuvant chemotherapy (NAC) + RC improves overall survival in MIBC compared with RC only. However, a new meta-analysis by Li et al. concluded that NAC + RC was not superior to RC only in improving overall survival. The inconsistencies of these studies required further comprehensive analysis to recommend NAC use in bladder cancer treatment. Therefore, this meta-analysis aims to analyze previous studies that compare the efficacy of NAC + RC versus RC only to improve overall survival of MIBC. Methods The articles were searched using Pubmed with keywords “muscle-invasive bladder cancer”, “neoadjuvant chemotherapy”, “cystectomy”, and “overall survival”. The articles that were published until June 2020 were screened. The overall survival outcome was analyzed as hazard ratio (HR) and presented in a forest plot. Result Seventeen studies were included in meta-analysis with a total sample of 13,391 patients, consist of 2890 received NAC followed by RC and 10,418 underwent RC only. Two studies used methotrexate/vinblastine/doxorubicin/cisplatin (MVAC), two studies used gemcitabine/cisplatin (GC), one study used Cisplatin-based regimen, one study used MVAC or GC, one study used gemcitabine/carboplatin (GCarbo) or GC or MVAC, one study used Cisplatin/Gemcitabine or MVAC, one study used Cisplatin only, one study used Cisplatin-based (GC, MVAC) or non-Cisplatin-based (combined paclitaxel/gemcitabine/carboplatin), one study used GC, MVAC, Carboplatin, or Gemcitabine/Nedaplatin (GN), and five studies did not mention the regimen The overall survival in the NAC + RC only group was significantly better than the RC only group (HR 0.82 [0.71–0.95], p = 0.009). Conclusion NAC + RC is recommended to improve overall survival in MIBC patients. A further study assessing side effects and quality of life regarding NAC + RC is needed to establish a strong recommendation regarding this therapy.


2019 ◽  
Vol 47 (10) ◽  
pp. 4604-4618 ◽  
Author(s):  
Hongbin Shi ◽  
Jiangsong Li ◽  
Kui Li ◽  
Xiaobo Yang ◽  
Zaisheng Zhu ◽  
...  

Background We performed a systematic review and meta-analysis to evaluate the efficacy and safety of minimally invasive radical cystectomy (MIRC) versus open radical cystectomy (ORC) for bladder cancer. Methods We searched the EMBASE and MEDLINE databases to identify randomized controlled trials (RCTs) of MIRC versus ORC in the treatment of bladder cancer. Results Eight articles describing nine RCTs (803 patients) were analyzed. No significant differences were found between MIRC and ORC in two oncologic outcomes: the recurrence rate and mortality. Additionally, no significant differences were found in three pathologic outcomes: lymph node yield, positive lymph nodes, and positive surgical margins. With respect to perioperative outcomes, however, MIRC showed a significantly longer operating time, less estimated blood loss, lower blood transfusion rate, shorter time to regular diet, and shorter length of hospital stay than ORC. The incidence of complications was similar between the two techniques. We found no statistically significant differences in the above outcomes between robot-assisted radical cystectomy and ORC or between laparoscopic radical cystectomy and ORC with the exception of the complication rate. Conclusions MIRC is an effective and safe surgical approach in the treatment of bladder cancer. However, a large-scale multicenter RCT is needed to confirm these findings.


PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e95667 ◽  
Author(s):  
Kun Tang ◽  
Heng Li ◽  
Ding Xia ◽  
Zhiquan Hu ◽  
Qianyuan Zhuang ◽  
...  

2016 ◽  
Vol 34 (5) ◽  
pp. 236.e13-236.e21 ◽  
Author(s):  
Suzanne B. Stewart-Merrill ◽  
Fares Alahdab ◽  
Khalid Benkhadra ◽  
Zhen Wang ◽  
Atsushi Sorita ◽  
...  

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Suzanne Stewart ◽  
Fares Alahdab ◽  
Khalid Benkhadra ◽  
Zhen Wang ◽  
Atsushi Sorita ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document